Ibrutinib combined with venetoclax treatment outcome in chronic lymphocytic leukemia: A systematic review

被引：0
|
作者：
Sugianto, Jeremy Octavian [1 ]
Purushotama, Nyoman Bagus Satcitta Ananda [1 ]
Ontowirjo, Yudi Ali Putra [1 ]
Sutanto, Mario [1 ]
Kurniawan, Andree [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.345
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P12-9
引用
收藏
页码：S1447 / S1447
页数：1
相关论文
共 50 条
  • [21] Ibrutinib in Treatment of Patients with chronic lymphocytic Leukemia
    Flammiger, A.
    ONKOLOGE, 2015, 21 (08): : 732 - 733
  • [22] Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review
    Sardar, Muhammad
    Malik, Saad Ullah
    Khan, Ali
    Idrees, Muhammad
    Ahmad, Qistas
    Sohail, Chaudhry
    Naseer, Raza
    Amin, Saher
    McBride, Ali
    Abuzar, Muhammad
    Safdar, Ahmed
    Chakraborty, Rajshekhar
    Lee, Patrick
    Sharon, David
    Anwer, Faiz
    JOURNAL OF HEMATOLOGY, 2019, 8 (01) : 1 - 10
  • [23] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [24] Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Lesley J. Scott
    Targeted Oncology, 2019, 14 : 493 - 504
  • [25] Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2019, 14 (05) : 493 - 504
  • [26] Ibrutinib for Chronic Lymphocytic Leukemia
    Sharman, Jeff P.
    Mato, Anthony R.
    Keating, Michael J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (16): : 1592 - 1593
  • [27] Treatment of relapsed chronic lymphocytic leukemia after venetoclax
    Thompson, Meghan C.
    Mato, Anthony R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 18 - 23
  • [28] IBRUTINIB: NEW TARGET TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Torres Iglesias, C.
    Torres Carrete, J. P.
    Vale Lopez, A.
    Deben Ariznavarreta, G.
    Noriega Concepcion, V
    Varela Gomez, R.
    Martinez Senaris, D.
    Martinez Gomez, C.
    Hevilla Carmona, A.
    Lopez Fernandez, F.
    HAEMATOLOGICA, 2019, 104 : 433 - 433
  • [29] Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
    Molica, Stefano
    Matutes, Estella
    Tam, Constantine
    Polliack, Aaron
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (02) : 129 - 136
  • [30] Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia
    Stephens, Deborah M.
    BLOOD, 2019, 134 (20) : 1691 - 1696
12345